KRAS G12C Mutations Archives

Amgen Hails Lumakras as Potential “Cornerstone” Medicine in Q3 Report

Business, Forecasts, KRAS G12C Mutations, Non-Small Cell Lung Cancer, Quarterly results, Sales, Therapeutics

Amgen Chairman and Chief Executive Officer Robert Bradway anticipates the non-small cell lung cancer drug Lumakras will become a cornerstone medicine as the company aims to develop multiple medications for targets long thought to be undruggable.

Mirati and Sanofi Unite on Trial for KRAS Inhibitor

Agreements, Business, Clinical Trials, Colorectal Cancer, Deals, G12C KRAS inhibitors, KRAS G12C Mutations, Non-Small Cell Lung Cancer, R&D, Sanofi, SHP2 inhibitors

Fresh off a presentation of positive data showing that the KRASG12C inhibitor adagrasib benefited colorectal and lung cancer patients, Mirati Therapeutics forged an agreement to combine the drug with Sanofi’s company’s SHP2 inhibitor SAR442720 in lung cancer.

Amgen’s KRAS Inhibitor Sotorasib Effective in Non-Small Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer, Cancer, Chemotherapy, Clinical Trials, Immunotherapies, KRAS G12C Mutations, Overall Response Rate (ORR), R&D, RAS Genes, Solid Tumors

Amgen presented positive topline data from the Phase II CodebreaK 100 trial of sotorasib in KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC).